Skip to main content

Table 1 Patient baseline characteristics by cohort

From: Preoperative prediction of peripancreatic vein invasion by pancreatic head cancer

 

Training cohort (n = 181)

Validation cohort (n = 66)

 

No. of patients

%

No. of patients

%

Gender

    

0.657

 Male

104

57.5

40

60.6

 

 Female

77

42.5

26

39.4

 

Age, years

    

0.986

 Median

65.0

64.0

 

 IQR

59.0–68.0

57.8–69.0

 

ADL

    

0.781

 Grade I

120

66.3

45

69.2

 

 > Grade I

61

33.7

21

31.8

 

Jaundice

    

0.210

 Yes

70

38.7

31

47.0

 

 No

111

61.3

35

53.0

 

Pain

    

0.481

 Yes

109

60.2

43

65.2

 

 No

72

39.8

23

34.8

 

Weight loss

    

0.730

 Yes

84

46.4

29

43.9

 

 No

97

53.6

37

56.1

 

CA 19–9, U/mL

    

0.313

 Median

280.4

439.1

 

 IQR

24.4–1614.1

53.9–2298.6

 

TB, μmol/mL

    

0.956

 Median

49.4

21.1

 

 IQR

11.2–151.1

11.1–182.9

 

Albumin, g/L

    

0.349

 Median

39.2

39.2

 

 IQR

36.1–41.8

36.6–43.7

 

Tumor staging on CT

    

/

 T1/T2

0

0

0

0

 

 T3

181

100

66

100

 

 T4

0

0

0

0

 

Lymph node staging on CT

    

0.698

 N0

80

44.2

31

47.0

 

 N1

101

55.8

35

53.0

 

M staging on CT

    

/

 M0

181

100

66

100

 

 M1

0

0

0

0

 

TNM staging on CT

    

0.698

 IA/IB

0

0

0

0

 

 IIA

80

44.2

31

47.0

 

 IIB

101

55.8

35

53.0

 

 III/IV

0

0

0

0

 

Tumor size on CT, cm

    

0.701

 Median

3.5

3.6

 

 IQR

2.8–4.6

2.8–4.44

 

Length of tumor contact on CT, cm

    

0.849

 Median

2.5

2.5

 

 IQR

2.0–3.0

2.0–3.0

 

Pathologic venous wall invasion

    

0.868

 Yes

152

84.0

56

84.8

 

 No

29

16.0

10

15.2

 

Surgical margin

    

0.146

 R0

163

90.1

55

83.3

 

 R1

18

9.9

11

16.7

 
  1. ADL activities of daily living, CA 19–9 carbohydrate antigen 19–9, TB total bilirubin, PV portal vein, SMV superior mesenteric vein